Per Persson,CEO, Acarix, presents at the VIRTUAL, 3rd annual BioStock Life Science Summit, where innovation and capital connect. Hosted jointly at BioStock's studio at the innovation super-cluster Medicon Village in Lund and our partner studio in Stockholm, the Summit is the Nordic region's premier showcase platform for the region's top early- and growth stage companies covering a number of therapeutic areas.
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, email@example.com) is Certified Advisor of Acarix.